Katherine Rigby

Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.

N. Steuerwald, P. Voorhees, D. Foureau, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

N. Steuerwald, P. Voorhees, D. Foureau, 2020, EJHaem.

Molecular Characterization By Immune Profiling of Paired Blood and Bone Marrow in Multiple Myeloma and Its Precursor States

N. Steuerwald, P. Voorhees, D. Foureau, 2018, Blood.

Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases

N. Steuerwald, P. Voorhees, D. Foureau, 2017 .

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

D. Foureau, T. Casneuf, L. Druhan, 2018, Experimental Hematology & Oncology.

A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.

P. Voorhees, D. Foureau, M. Pineda‐Roman, 2023, Clinical lymphoma, myeloma & leukemia.

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma

P. Voorhees, D. Foureau, M. Bhutani, 2021, Cancer medicine.